Measurement of Distinct Biological Pools of Hydrogen Sulfide in Women With Cardiovascular Disease

August 30, 2021 updated by: Christopher Kevil, Louisiana State University Health Sciences Center Shreveport
Cardiovascular disease which includes coronary artery disease and peripheral artery disease remains the leading cause of death among women in the United States. The impact of cardiovascular in women was not recognized by clinicians for a long time. It is now evident that, women suffer the consequences of cardiovascular at rates at least as high as those observed in men but there are still major gaps in our understanding this disease in women. Hydrogen sulfide (H2S), a gaseous mediator plays an important role in the cardiovascular system. Research has demonstrated it's critical role in animal ischemia reperfusion models. Hydrogen sulfide exists in distinct biological pools in blood. Recently, the Kevil lab has pioneered the development of new analytical techniques for accurate measurement of all biological pools of H2S. By measuring these distinct pools of H2S in women with and without cardiovascular disease the investigators hope to further understanding of role of H2S in pathophysiology of cardiovascular disease. This research will help to assess the ability of H2S and its distinct biological pools to potentially be a diagnostic marker or a therapeutic target for cardiovascular disease.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

137

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Louisiana
      • Shreveport, Louisiana, United States, 71103
        • LSUHSC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Female subjects scheduled to undergo left heart catheterization or peripheral angiography at LSUHSC Shreveport cardiac catheterization laboratory will be given the opportunity to participate. Controls will be recruited via flyers posted in various parts of LSUHSC Shreveport.

Description

Inclusion Criteria:

  1. Patients presenting to the cardiac catheterization laboratory for coronary or peripheral angiography.
  2. Females,Age>40years

Exclusion Criteria:

  1. Inability to provide informed consent.
  2. STelevationmyocardialinfarction.
  3. Cardiogenicshock.

3. ABI >1.4 (indicative of non-compressible vessel needing further evaluation to diagnose PAD), unless documented known PAD. 4. Non-atheroscleroticPAD(e.g.Buerger'sdisease). 5. Enrolment in another clinical trial with use of experimental therapeutic agents.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
I
Women without PAD (ABI >1.0 and <1.4) or CAD, and < 2 risk factors for cardiovascular disease (to serve as healthy controls)
II
Women without PAD (ABI>1.0 and <1.4) or CAD and > 2 risk factors for cardiovascular disease
III
Women with PAD as defined by ABI <0.9 and a coronary angiogram without any significant coronary artery disease.
IV
Women with CAD without PAD, as defined by >50% stenosis by coronary angiography and ABI >1.0 and <1.4.
V
Women with both CAD and PAD.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Free Sulfide, Bound Sulfide and Acid Labile Sulfide
Time Frame: 1 year
Unit of Measure: nMol
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Louisiana State University Health Sciences Center Shreveport

Investigators

  • Principal Investigator: Christopher Kevil, PhD, LSUHSC Shreveport

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2013

Primary Completion (Actual)

May 7, 2017

Study Completion (Actual)

May 7, 2017

Study Registration Dates

First Submitted

March 18, 2014

First Submitted That Met QC Criteria

June 30, 2014

First Posted (Estimate)

July 2, 2014

Study Record Updates

Last Update Posted (Actual)

September 2, 2021

Last Update Submitted That Met QC Criteria

August 30, 2021

Last Verified

June 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SRKH2SPOOLS

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe